YM 207Alternative Names: Humanised anti-C4G1 monoclonal antibody; Y1-antibody
Latest Information Update: 22 Sep 1998
At a glance
- Originator Yamanouchi
- Class Antiplatelets; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Arterial thrombosis; Myocardial infarction